Why Abbott is paying $21 billion for Exact Sciences and its Cologuard cancer test

Abbott is getting into the cancer-testing game with its $21 billion acquisition of Cologuard test maker Exact Sciences.
Nasdaq

Abbott Receives FDA Approval for HPV Test to Run on Alinity m, Offering Primary HPV Screening and Assessment of High-Risk Cancer-Causing Types of HPV

ABBOTT PARK, Ill., Nov. 2, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) has received U.S. Food and Drug Administration (FDA) approval for its molecular human papillomavirus or HPV screening solution, ...
Crain's Chicago Business

Abbott adds HPV primary screening to Alinity test family

Abbott Laboratories is adding HPV screening to its "Alinity m" family of diagnostic assays following U.S. Food & Drug Administration approval. Abbott said in a press release that the FDA approved its ...
Dealbreaker on MSN

Abbott’s $23B Bet on Exact Sciences: Bold Move or Risky Gamble?

Experts think the deal makes strategic sense, as it offers higher margins and a broader commercial scale — but questions ...
Crain's Chicago Business

Abbott concussion test OK'd for bedside application

A concussion test that Abbott Labs hopes someday could be used by sports team trainers and at urgent care clinics is now available for rapid use at the bedside, without having to send a sample to a ...
Seeking Alpha

Abbott Receives FDA Approval for HPV Test to Run on Alinity m, Offering Primary HPV Screening and Assessment of High-Risk Cancer-Causing Types of HPV

According to the U.S. Centers for Disease Control (CDC), most sexually active adults will experience HPV infections; new test detects those HPV genotypes that could lead to cancer Abbott (ABT)'s new ...